详情页 - 首都医科大学附属北京同仁医院知识库

资源类型：

文章类型：

作者：

Song, Yuqin[1] * ; Zhou, Keshu[2,3] ; Jin, Chuan[4] ; Qian, Zhengzi[5] ; Hou, Ming[6] ; Fan, Lei[7] ; Li, Fei[8] ; Ding, Kaiyang[9] ; Zhou, Hui[10] ; Li, Xiaoling[11] ; Chen, Bing[12] ; Sun, Xiuhua[13] ; Song, Xianmin[14] ; Jiang, Ming[15] ; Zhang, Qingyuan[16] ; Liu, Lihong[17] ; Yu, Guohua[18] ; Hu, Yu[19] ; Zhao, Zheng[20] ; Liu, Ligen[21] ; Xue, Hongwei[22] ; Luo, Jun[23] ; He, Bai[24] ; Jin, Xiaoping[25] ; Wang, Maxwell[25] ; Li, Baiyong[25] ; Xia, Yu[25] ; Zhu, Jun[26] ;

机构： [1]Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China [2]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China [3]Henan Canc Hosp, Zhengzhou, Henan, Peoples R China [4]Guangzhou Med Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China [5]Tianjin Med Univ Canc Inst & Hosp, Sino US Ctr Lymphoma & Leukemia Rese, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China [6]Shandong Univ, Qilu Hosp, Shandong Prov Key Lab Immunohematol, Qilu, Peoples R China [7]Nanjing Med Univ, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Affiliated Hosp 1, Nanjing, Peoples R China [8]Nanchang Univ, Nanchan, Peoples R China [9]Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, USTC, Hefei, Anhui, Peoples R China [10]Cent South Univ, Xiangya Sch Med, Tumor Hosp, Changsha, Hunan, Peoples R China [11]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China [12]Nanjing Med Univ, Clin Coll, Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China [13]Dalian Med Univ, Affiliated Hosp 2, Dalian, Peoples R China [14]Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai, Peoples R China [15]Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Sichuan, Peoples R China [16]Heilongjiang Prov Hosp, Harbin, Heilongjiang, Peoples R China [17]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [18]Weifang Peoples Hosp, Weifang, Peoples R China [19]Tongji Med Coll, Union Hosp, Wuhan, Hubei, Peoples R China [20]Shanxi Prov Canc Hosp, Xian, Shaanxi, Peoples R China [21]Shanghai Tongren Hosp, Shanghai, Peoples R China [22]Qingdao Univ, Affiliated Hosp, Qingdao, Shandong, Peoples R China [23]Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China [24]First Peoples Hosp Changzhou, Changzhou, Jiangsu, Peoples R China [25]Akeso Biopharma Inc, Potomac, MD USA [26]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 1 区

医学

小类 | 1 区免疫学 2 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区免疫学 2 区肿瘤学

JCR分区：

出版当年[2018]版：

Q1 ONCOLOGY Q1 IMMUNOLOGY

最新[2024]版：

Q1 IMMUNOLOGY Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

A PHASE II STUDY OF THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTIBODY PENPULIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL)

文献详情